FP7Individual fellowship2012–2014

SELECTIPROBE · Development of selective antagonists and subtype selective ligands for the D-myo-inositol 1,4,5-trisphosphate receptors.""

FP7 — People (Marie Curie Actions)

Duration
2012-06-01 → 2014-05-31
EU contribution
€200,372
Participants
1
Scheme
MC-IEF

Lines connect the coordinator with its partners.

Results in brief

Development of selective antagonists and subtype selective ligands for the D-myo-inositol 1,4,5-trisphosphate receptors.

Synthesis and development of small molecule probes for the intracellular Ca2+-releasing D-myo-inositol 1,4,5-trisphosphate receptors (InsP3Rs) During these two years the following results have been achieved, according to the planning proposed: - Synthesis of thiazolidinones, TZD and IZD derivatives as phosphate bioisosteres fragments for identifying binding interactions with the HGSA protein. - Identification of binding effects with the HGSA protein by the STD NMR technique. Most of the thiazolidinone amides compounds presented an inhibition activity towards this protein, showing the first non-phosphorus small inhibitors of the HGSA protein. - This project has demonstrated that an approach to screening proteins by STD NMR using a fragment library based on phosphate bioisosteres can rapidly produce evidence of binding and may be of use in finding suitable ligands for other phosphate binding sites. - The solubility problem of synthesized compounds in aqueous media has prevented us from making measurements of the dissociation constant Kd by NMR experiments. However, it was possible to get them by ITC method. We showed that the Kd of our compounds are much higher than the inositol-1,3-biphosphate (InsP2). - We managed to have the crystal structure of three thiazolidinone compounds in the presence of the HGSA protein. The validation of these crystals remains to be confirmed, but can be very useful for docking studies. We have already used this information to our modeling experiments in order to make a selection of potential good inhibitors of this protein and will be useful for the continuity of the project. Future work Working on this project has been very exciting and frustrating at the same time. This project still has plenty to develop, but time is short and we must pass the role to someone else who I'm sure will bring the project further. The first priority will be to validate the STD NMR hits from some of the fragments by using alternative assays. This will not only provide a secondary determination of binding, but may allow for a quantitative estimation of affinity. The crystal structures had been obtained, even with the doubt of their validation, we were able to make docking studies and select a group of molecules that can be good inhibitors for HGSA protein. Their synthesis and tests will be carried out. It would be interesting to see the effects that these modifications would have on binding interactions. During these two years, from the preliminary results we obtained and which were satisfactory and encouraging for the rest of the project, two Part II students (one each year) developed two new series of compounds with other phosphate bioisosteres than the ones developed in this report. Future work of this project will be to continue to develop new structures using the docking experiments, to combine our three results obtained with compounds contained different phosphates bioisosteres and try to get out and have the most effective inhibitor of the HGSA protein.

Data: CORDIS, © European Union

Project objective

The overall aim of this project is the development of novel ligands to probe the role of D-myo-inositol 1,4,5-trisphosphate receptors (InsP3Rs) in intracellular calcium signalling. Two key goals are the development of selective and potent non-inositol InsP3R antagonists and the development of ligands that bind selectively to one of the three subtype of InsP3Rs. Using hits from an in silico screen, we will develop and then employ thermal shift analysis, surface plasmon resonance and isothermal titration calorimetry assays to identify promising lead compounds. We will determine whether these compounds act as agonists or antagonists using a fluorescence-based sea urchin egg homogenate assay before data are obtained in further, more intact, cellular assays. In order to facilitate the use of these compounds in cells they will be rendered cell permeant using previously developed technology. X-ray crystallographic studies with these compounds, in particular the antagonists, will be undertaken in order to shed light the molecular mechanism of InsP3R activation. Subtype selective ligands will be useful in determining the particular role of each of the InsP3R subtypes in normal cellular function and cellular dysfunction, which underlies diseases such as heart arrhythmia and cardiac hypertrophy. This project has been designed to capitalise on the skills of the fellow in chemical synthesis and her knowledge of phosphate bioisosteres. Further advanced training will be provided in chemical synthesis, biophysical techniques and molecular biology in addition to cooperation with industrial collaborators Inhibox. Consequently, the fellow will significantly enhance and diversify her skills in this highly multidisciplinary project.""

Original text from CORDIS.

Participants

  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD · OxfordCoordinatorUnited Kingdom

Links

Data: CORDIS, © European Union